Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096064 · ClinicalTrials.gov registry record
Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 100
- Enrollment target
NCT06096064: Completed study, sponsored by Methodist Health System.
NCT06096064 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06096064 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
Primary Outcome
Appropriate anticoagulation management will be measured using Percent time in therapeutic range based on aPTT levels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2023-08-21 |
What the finished NCT06096064 record still lists
NCT06096064 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06096064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06096064 about?
NCT06096064 is a clinical study titled "Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients". Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus foll...
What is the current status of trial NCT06096064?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2022-10-31. Estimated completion is 2023-08-21.
Who is sponsoring clinical trial NCT06096064?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI